Business Irish

Wednesday 18 September 2019

AIM-listed Integumen buys Scottish men's skincare business in all-share deal

Integumen chief executive Declan Service said the deal will help speed up revenue generation
Integumen chief executive Declan Service said the deal will help speed up revenue generation
Gavin McLoughlin

Gavin McLoughlin

Irish personal healthcare business Integumen has bought Scottish men's skincare business Stoer & Co for more than £500,000 (€560,000).

The company - listed on the AIM market in London - said the deal would provide "significant economies of scale as its builds its infrastructure".

Integumen floated earlier this year, raising £2.25m, with products focused on the areas of skincare, oral care and wound care.

Its IPO price was 5p - the shares are now trading at just under 2.5p.

Chief executive Declan Service said the Stoer deal "supports [Integumen's] objective of broadening our portfolio of products and accelerating revenue generation".

"The brand has been well-received by the market and is well suited to bloggers and social media and we are currently in discussions to expand its distribution channels both in the UK and overseas".

The deal is being paid for via the issuing of new Integumen shares to the seller - Chess Group Investment Company.

A separate tranche of shares is being issued to Chess chairman James Barrack.

"Further new products are currently being developed under the Stoer brand for the male grooming market. Two SPF products have been formulated and are about to commence stability testing and three shave range products are in early stage development which may be commercialised by the brand directly or in collaboration with an already established shave franchise," Integumen said.

Integumen is chaired by Venn Life Sciences boss Tony Richardson, who founded the business alongside Service.

The men worked together at Venn Life Sciences and Integumen went on to acquire one of Venn Life Sciences' subsidiaries.

Integumen posted an operational loss of just under £1.4m in the six months to the end of June, on revenues of £124,310 and administrative costs of £1,476,057.

This included the cost of listing on AIM, amortisation and depreciation of assets and investment in a number of products.

The company was set up "to focus on commercialising technologies in the health and personal care products market which are either on the market or at an advanced stage of product development".

Its portfolio includes tongue vacuum cleaner TS1 and anti-blemish product Clarogel.

Sunday Indo Business

Also in Business